Document is current
Any future updates will be listed below
-
Authors
Berry, Andrea A.
Richie, Thomas L.
Church, L. W. Preston
Laurens, Matthew B.
Boyce, Colleen
KC, Natasha
Joshi, Sudhaunshu
Koudjra, Abra Rachida
Butler, Lauryn
Chen, Mei-Chun
Abebe, Yonas
Murshedkar, Tooba
James, Eric R.
Billingsley, Peter F.
Sim, B. Kim Lee
Hoffman, Stephen L.
Lyke, Kirsten E.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05604521 at ClinicalTrials.govDocuments that mention this clinical trial
Safety, tolerability and immunogenicity of a condensed, multi-dose prime regimen of PfSPZ Vaccine for the prevention of Plasmodium falciparum malaria infection
https://doi.org/10.1186/s12936-025-05299-5
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases,United States (U44AI167783)
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 18 February 2025
First Online: 17 March 2025
Declarations
:
: The clinical protocol was reviewed and approved by the WCG investigational review board.
: T.L.R., L.W.P.C., N.K.C., M.C.C., Y.A., T.M., E.R.J. P.F.B., B.K.L.S., and S.L.H were salaried, full-time employees of Sanaria Inc at the time of this study. B.K.L.S. and S.L.H. own stock in Sanaria.
